FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron)

[09-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public of an ongoing safety review of the anti-nausea drug Zofran (ondansetron, ondansetron hydrochloride and their generics).

Source: FDA Center for Drug Evaluation and Research - What's New - June 28, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news